更新于：2024-11-21

Jaungo

更新于：2024-11-21

概要

研发状态

概要

基本信息

药物类型

中药

别名

Shiunko、composed of Lithospermi radix and Angelica sinensis. Lithospermi radix contains shikonin, acetylshikonin, dimethyacrylshikonin, deoxyshikonin, and isobutylshikonin

靶点-

作用机制-

治疗领域

免疫系统疾病遗传病与畸形皮肤和肌肉骨骼疾病

在研适应症-

非在研适应症

特应性皮炎

原研机构

Kyung Hee University Hospital at Gangdong

在研机构-

非在研机构

Kyung Hee University Hospital at Gangdong

最高研发阶段无进展临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

项与 Jaungo 相关的临床试验

NCT02900131 / Completed临床2期IIT

Efficacy, Safety and Dose Finding Trial of Topical Jaungo Application in Atopic Dermatitis Patients: a Randomized, Double-blind, Placebo-controlled Study

Atopic Dermatitis is a chronic relapsing eczematous skin disease with increasing prevalence. Complementary and alternative medical approaches have been employed to relieve symptoms of Atopic Dermatitis. We aim to establish basic clinical efficacy and safety data for Jaungo in patients with Atopic Dermatitis.

开始日期2016-09-19

申办/合作机构

Kyung Hee University Hospital at Gangdong

100 项与 Jaungo 相关的临床结果

登录后查看更多信息

100 项与 Jaungo 相关的转化医学

登录后查看更多信息

100 项与 Jaungo 相关的专利（医药）

登录后查看更多信息

项与 Jaungo 相关的文献（医药）

2024-01-01·Integrative Cancer Therapies

Potential Efficacy of Shiunko for Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody-Induced Skin Fissure: A Single Institutional Case Series

Article

作者: Mishima, Saori ; Kawazoe, Akihito ; Kotani, Daisuke ; Nakamura, Maho ; Shitara, Kohei ; Yoshino, Takayuki ; Bando, Hideaki ; Okunaka, Mashiro

Purpose: Anti-epidermal growth factor receptor monoclonal antibody (anti-EGFR mAb) is the key drug for RAS/ BRAF V600E wild-type metastatic colorectal cancer (mCRC). However, anti-EGFR mAb-induced skin fissures often affect a patient’s quality of life. Shiunko, a traditional Japanese topical herbal medicine, is used for burns and dermatitis and may potentially have wound-healing effects. Herein, we report cases of patients with mCRC who were treated with Shiunko for anti-EGFR mAb-induced skin fissure. Methods: We retrospectively reviewed consecutive patients with mCRC who received an anti-EGFR mAb-containing regimen and were treated with Shiunko twice a day for skin fissures at the National Cancer Center Hospital East between March 2022 and December 2022. Skin fissures were assessed at baseline and at every visit until 28 days after Shiunko initiation according to CTCAE v5.0. Results: Among the 11 patients, 5 patients were female; the median age was 61 (range, 43-79) years. The median treatment duration with anti-EGFR mAb before Shiunko initiation was 13.1 (range, 6-52) weeks. Skin moisturizer and topical steroids were applied for skin fissures in 11 and 5 patients, respectively. All patients had grade 2 skin fissures at baseline of Shiunko initiation. Two weeks after Shiunko initiation, complete recovery was noted in 4 patients and improvement to grade 1 was noted in 6 patients. There were no Shiunko-related adverse events. Ten patients continued anti-EGFR mAb treatment until disease progression, while 1 patient discontinued anti-EGFR mAb treatment due to severe eruptions. Conclusion: Shiunko could be a treatment option for anti-EGFR mAb-induced skin fissure. Further studies are warranted to investigate the efficacy and safety of Shiunko for anti-EGFR mAb-induced skin fissure.

2019-09-30·Journal of Pharmacopuncture

Post Treatment Application of Jaungo after a Combined Therapy of Carbon Dioxide Laser and Trichloroacetic Acid in a Case of Vulvar Syringoma

作者: Kim, Wonnam ; Kim, En Hyung

Syringoma is a benign eccrine sweat gland tumor that predominantly appears in females during puberty with multiple smooth papules measuring 1-2 mm in diameter. Common locations are on lower eyelids and cheeks. Vulvar syringoma is quite a rare, occurring condition with only a few cases reported. Here, we are reporting a case of 31-year-old female with vulvar syringoma associated with pruritus. The lesion was treated with carbon dioxide (CO2) laser ablation and 50% trichloroacetic acid (TCA) chemical peeling. Jaungo was used for wound care after laser abrasion. The combination treatment was effective for removing syringoma lesions. Post laser management with fusidic acid cream and jaungo cream was sufficient to prevent infection and promote wound healing.

2019-04-01·Medicine4区 · 医学

Effectiveness, safety, and economic evaluation of topical application of a herbal ointment, Jaungo, for radiation dermatitis after breast conserving surgery in patients with breast cancer (GREEN study)

4区 · 医学

ArticleOA

作者: Lim, Yu Jin ; Jang, Bo-Hyoung ; Suh, Hae Sun ; Shin, Seungwon ; Yoon, Seong Woo ; Lee, Jin-Wook ; Park, Seung-Hyeok ; Hwang, Deok-Sang ; Kong, Moonkyoo

AbstractIntroduction:This is a prospective, open-label, parallel-group, randomized controlled trial that evaluates the effectiveness and safety of adjuvant application of Jaungo (JUG) for radiation-induced dermatitis (RD) in breast cancer patients undergoing radiation therapy, in comparison with general supportive care (GSC).Methods/design:Eighty female patients, who have been diagnosed with unilateral breast cancer, will be allocated to either the JUG or GSC group with an allocation ratio of 1:1 after breast conservation surgery, in the Kyung Hee University Korean Medicine Hospital, Seoul, Republic of Korea. Both the groups will be subjected to GSC, but only the JUG group participants will apply adjuvant JUG ointment on the irradiated skin for 6 weeks, twice a day. The primary outcome of this study is the assessment of incidence rate of RD using the Radiation Therapy Oncology Group (RTOG) for toxicity gradation of 2 or more. Maximum pain level, quality of life, adverse reactions, and pharmacoeconomic evaluations will also be included.Discussion:The primary outcome will be statistically compared using the logrank test after estimating the survival curve using the Kaplan–Meier method. Continuous variables will be tested using independent t test or Mann–Whitney U test. The adverse events will be evaluated with Chi-square or Fisher exact test. All the data will be analyzed at a significance level of 0.05 (two-sided) with R software (The R Foundation).Trial registration:CRIS (Clinical Research Information Service), KCT0003506, 14 February 2019.

100 项与 Jaungo 相关的药物交易

登录后查看更多信息